Video

How Water Vapor Therapy Works

August 31, 2020

This video demonstrates how water vapor therapy will provide a revolutionary new prostate cancer treatment that is tough on prostate cancer yet gentle on patients.

Share this post

Recent Posts

  • Dr. Samir Taneja and Northwell Urology team celebrate first commercial Vanquish Water Vapor Ablation procedure in New York
Francis Medical Announces Northwell Urology Group Performs First Commercial Vanquish® Water Vapor Ablation Procedure in New York

August 5th, 2026|

LAKE SUCCESS, NY, August 5, 2026, - Samir S. Taneja, MD, a urologic oncologist, chairman of the Department of Urology at Northwell Health and professor of urology at the Donald and Barbara Zucker School of Medicine, has performed the first commercial Vanquish® Water Vapor Ablation (Vanquish System) procedure in New York state, marking a significant milestone for patients in the region seeking a minimally invasive prostate care option.

  • Dr. Su
Francis Medical Announces Orange County Urology Associates Becomes First in California to Integrate Vanquish® Water Vapor Ablation into Routine Prostate Care

July 7th, 2026|

Maple Grove, Minn., July 7th, 2026 – Daniel Su, MD, a urologist at Orange County Urology Associates (OCUA), has performed the first commercial Vanquish® Water Vapor Ablation procedures in the state of California, offering patients a new minimally invasive Focal Therapy option as part of the group’s prostate care service. The procedure was completed within a single outpatient visit and did not require a hospital stay. Beyond the clinical milestone, Dr. Su’s experience highlights something equally important: how this technology can be adopted into an existing urology practice.

Francis Medical Announces Publication of VAPOR 2 Pivotal Trial Results in The Journal of Urology

June 30th, 2026|

MAPLE GROVE, Minn., June 30, 2026 – Francis Medical, Inc., a medical device company dedicated to advancing minimally invasive therapies for urological cancers, today announced the publication of the initial report from its VAPOR 2 pivotal clinical study in The Journal of Urology, one of the world’s leading peer-reviewed urology journals.